A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing Friday at 27. After 12 companies submitted their initial filings with the SEC in the first week of the year, just three...read more
As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same day Voyager had the best pop in almost two months (+27%). While there were no biotech filings this past week, it is a safe...read more
Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue. Only one of the four priced below the range, compared to 85% of IPOs that began trading in October. Advanced Accelerator Applications (AAAP) popped 53%, giving it the best first-day performance for an IPO in the past three months. The diagnostics/therapeutics...read more
Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, raised $70 million by offering 5.0 million shares at $14, below the range of $15 to $17. It had originally planned to offer 4.69 million shares. Voyager Therapeutics plans to list on the Nasdaq under the symbol VYGR. Cowen & Company and Piper Jaffray acted as lead managers on...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
US IPO Weekly Recap: The only IPO delays as the market falls for the second straight week
A bad start to the year only got worse this week as the S&P 500 fell another 2%. For the first time since October, the ninety-day returns swung negative to -0.6%. Just two weeks ago, that number stood at 17%. The VIX is up 48% year-to-date, closing Friday at 27. After 12 companies submitted their initial filings with the SEC in the first week of the year, just three...read more
US IPO Weekly Recap: IPO market turns friendly as seven companies go public
As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same day Voyager had the best pop in almost two months (+27%). While there were no biotech filings this past week, it is a safe...read more
Good trading if you can get it (done): Four of six IPOs price and trade up on Wednesday
Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue. Only one of the four priced below the range, compared to 85% of IPOs that began trading in October. Advanced Accelerator Applications (AAAP) popped 53%, giving it the best first-day performance for an IPO in the past three months. The diagnostics/therapeutics...read more
Parkinson's biotech Voyager Therapeutics prices IPO below range at $14
Voyager Therapeutics, a gene therapy biotech targeting Parkinson's disease and other CNS disorders, raised $70 million by offering 5.0 million shares at $14, below the range of $15 to $17. It had originally planned to offer 4.69 million shares. Voyager Therapeutics plans to list on the Nasdaq under the symbol VYGR. Cowen & Company and Piper Jaffray acted as lead managers on...read more